The Serotonin System

History, Neuropharmacology, and Pathology
Erscheinungsjahr 2019
ISBN: 978-0-12-813323-1
Verlag: Elsevier Science

Buch, Englisch, 306 Seiten, Format (B × H): 152 mm x 226 mm, Gewicht: 522 g

The Serotonin System: History, Neuropharmacology, and Pathology provides an up-to-date accounting on the physiology and pathophysiology of serotonin and the role it plays in behavioral functions. In addition, the book explores the potential roles of 5-HT1 in neurodevelopmental disorders and summarizes the history of the discovery and development of serotonergic drugs for the treatment of neuropsychiatric disorders. This concise, yet thorough, volume is the perfect introduction to this critical neurotransmitter. It is ideal for students and researchers new to the study of behavior, neuropsychiatry or neuropharmacology, but is also a great resource for established investigators who want a greater perspective on serotonin.

Zielgruppe

Researchers, advanced students, and postdocs in neuroscience, psychiatry, pharmacology, and related areas with interests in the physiology and pharmacology of the serotonergic system in the animal and human brain

Autoren/Hrsg.

Tricklebank, Mark

Daly, Eileen

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Neuropharmakologie, Psychopharmakologie
• Naturwissenschaften Biowissenschaften Biowissenschaften Neurobiologie, Verhaltensbiologie
• Interdisziplinäres Wissenschaften Wissenschaften Interdisziplinär Neurowissenschaften, Kognitionswissenschaft

Inhaltsverzeichnis

1. The metabolism of indoleamines 2. Neurodevelopmental Roles and The Serotonin Hypothesis of Autism Spectrum Disorder 3. The role of serotonin receptors in the control of cardiovascular function 4. Serotonin Receptors Nomenclature 5. A perspective: from the serotonin hypothesis to cognitive neuropsychological approaches 6. Endocrine and genetic moderation of serotonin systems and the psychopathology of affective disorders 7. Serotonin and sexual behavior 8. Serotonin and cognitive flexibility 9. Serotonin and Aggression 10. Serotonin and Sleep 11. Serotonin and the Psychedelics 12. Serotonin and nociception: from nociceptive transduction at the periphery to pain modulation from the brain 13. Serotonin and Feeding Regulation 14. The outlook for the development of serotonergic drugs as therapeutic medications for psychiatric disorders

Über Autor(innen)

Daly, Eileen
Dr Eileen Daly, PhD, is a Senior Lecturer in the Department of Forensic and Neurodevelopmental Sciences at King's College London. When at the National Institute of Aging, National Institutes of Health, USA, she measured neurotransmitter metabolites in human CSF and rodent brain. Relocating to the Institute of Psychiatry in London, she completed her PhD in Developmental Neuroscience with a project using Acute Tryptophan Depletion to modulate serotonin in Autism Spectrum Disorder, then looking at the brain with fMRI. She continues to study the role of neurotransmitters in developmental disorders and is the author of more than 100 papers.

Tricklebank, Mark
Dr. Mark David Tricklebank, BSc MSc PhD DSc FBphS, earned his PhD from the University of Manchester, and after completing postdoctoral training at the Institute of Neurology, he joined the pharmaceutical company Merrell Dow in Strasbourg, where he was instrumental in the identification of the functional relevance of the newly identified 5-HT1A recognition site. He then moved to Merck at Terlings Park, where he worked with Susan Iversen to identify the behavioral effects of the NMDA receptor antagonist MK-801 and showed them to be identical to those of phencyclidine and ketamine. After then serving as head of the Mental Health Unit at Sandoz Pharma in Basel, he was appointed director of In Vivo Pharmacology at the Lilly Research Centre, Windlesham, where he conceived and founded the Lilly Centre for Cognitive Neuroscience, one of the first industrial-academic partnerships in the United Kingdom. After a varied career of several decades in the pharmaceutical industry, he now serves as a Wellcome Trust Fellow in the Institute of Psychiatry, Psychology and Neuroscience at King's College London, and has published more than 160 papers.